Opposite effects of two PKA inhibitors on cAMP inhibition of IGF-I-induced oligodendrocyte development: A problem of unspecificity?

Brain Research

Volumn 1178, Issue 1, 2007, Pages 1-11

  Palacios, Nuria ^a   Sánchez Franco, Franco ^b   Fernández, Miriam ^a   Sánchez, Isabel ^a   Villuendas, Gemma ^a   Cacicedo, Lucinda ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

cAMP; cAMP dependent protein kinase; H89; Insulin like growth factor I; Mitogen activated protein kinase

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; FORSKOLIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYELIN BASIC PROTEIN; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; SOMATOMEDIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CELL MATURATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SPECIFICITY; IMMUNOCYTOCHEMISTRY; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANIMALS, NEWBORN; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELLS, CULTURED; CULTURE MEDIA; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENZYME ACTIVATION; ENZYME INHIBITORS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR I; ISOQUINOLINES; MITOGEN-ACTIVATED PROTEIN KINASES; MYELIN BASIC PROTEINS; OLIGODENDROGLIA; RATS; RATS, SPRAGUE-DAWLEY; SUBSTRATE SPECIFICITY; SULFONAMIDES; THIONUCLEOTIDES;

EID: 35448986845     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.07.018     Document Type: Article

References (58)

1. Afshari F.S., Chu A.K., and Sato-Bigee C. Effect of cyclic AMP on the expression of myelin basic protein species and myelin proteolipid protein in commited oligodendrocytes: differential involvement of the transcription factor CREB. J. Neurosci. Res. 66 (2001) 37-45
2. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem. 72 (1976) 248-254
3. Carson M.J., Behringer R.R., Brinster R.L., and McMorris F.A. Insulin-like growth factor I increases brain growth and central nervous system myelination in transgenic mice. Neuron 10 (1993) 729-740
4. Chang H.S., Jeon K.W., Kim Y.H., Chung I.Y., and Park C.S. Role of cAMP-dependent pathway in eosinophil apoptosis and survival. Cell. Immunol. 203 (2000) 29-38
5. Chen C., and Reghr W.R. The mechanism of cAMP-mediated enhancement at a cerebellar synapse. J. Neurosci. 17 (1997) 8687-8694
6. Choi J.S., Choi B.H., Hahn S.J., Yoon S.H., Min D.S., Jo Y.H., and Kim M.S. Inhibition of Kv1.3 channels by H89 (N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide) independent of protein kinase A. Biochem. Pharmacol. 61 (2001) 1029-1032
7. Cui Q.L., and Almazán G. IGF-I-induced oligodendrocyte progenitor proliferation requires PI3K/Akt, MEK/ERK, and Src-like tyrosine kinases. J. Neurochem. 100 (2007) 1480-1493
8. D'Angelo G., Lee H., and Weiner R.I. cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation. J. Cell. Biochem. 67 (1997) 353-366
9. Davies S.P., Reddy H., Caivano M., and Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351 (2000) 95-105
10. Dumont J.E., Jauniaux J.C., and Roger P.P. The cyclic AMP-mediated stimulation of cell proliferation. Trends Biochem. Sci. 14 (1989) 67-71
11. Fredriksson J.M., and Nedergaard J. Norepinephrine specifically stimulates ribonucleotide reductase subunit R2 gene expression in proliferating brown adipocytes: mediation via a cAMP/PKA pathway involving Src and Erk1/2 kinases. Exp. Cell Res. 274 (2002) 207-215
12. Graves L.M., Bornfeldt K.E., Raines E.W., Potts B.C., Macdonald S.G., Ross R., and Krebs E.G. Protein kinase A antagonizes platelet-derived growth factor-induced signalling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 10300-10304
13. Gross A., Bouaboula M., Casellas P., Liataurd J.P., and Dornand J. Subversion and utilization of the host cell cyclic adenosine 5′-monophosphate/protein kinase A pathway by Brucella during macrophage infection. J. Immunol. 170 (2003) 5607-5614
14. Helmeste D.M., and Tang S.W. Kinase inhibitors compete with imipramine for binding and inhibition of serotonin transport. Eur. J. Pharmacol. 267 (1994) 239-242
15. Hordijk P.L., Verlaan I., Jalink K., van Coreven E.J., and Moolenaar W.H. cAMP abrogates the p21ras-mitogen-activated protein kinase pathway in fibroblasts. J. Biol. Chem. 269 (1994) 3534-3538
16. Indolfi C., Avvedimento E.V., Di Lorenzo E., Esposito G., Rappacciuolo A., Giuliano P., Grieco D., Cavuto L., Stignone A.M., Ciullo I., Condrorelli G., and Chiariello M. Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury. Nat. Med. 3 (1997) 775-779
17. Kawasaki H., Springett G.M., Mochizuki N., Toki S., Nakaya M., Matsuda M., Housman D.E., and Graybiel A.M. A family of cAMP-binding proteins that directly activate Rap1. Science 282 (1998) 2275-2279
18. 2+ pumps by H89. Biochem. Pharmacol. 54 (1997) 991-998
19. Lee T.H., and Linstedt A.D. Potential role for protein kinases in regulation of bidirectional endoplasmic reticulum- to Golgi transport revealed by protein kinase inhibitor H89. Mol. Biol. Cell 11 (2000) 2577-2590
20. Leehmius J., Boutillier S., Schmidt G., and Meyer D.K. The protein kinase A inhibitor H89 acts on cell morphology by inhibiting Rho kinase. J. Pharmacol. Exp. Ther. 300 (2002) 1000-1007
21. Leong H., Riby J.E., Firestone G.R., and Bjeldanes L.F. Potent ligand-independent estrogen receptor activation by 3,3′-diindolylmethane is mediated by cross-talk between the protein kinase A and mitogen-activated protein kinase signaling pathways. Mol. Endocrinol. 18 (2004) 291-302
22. Mason J.L., Ye P., Suzuki K., D'Ercole A.J., and Matsushima G.K. Insulin-like growth factor-1 inhibits mature oligodendrocyte apoptosis during primary demyelination. J. Neurosci. 20 (2000) 5703-5708
23. Mason J.L., Xuang S., Dragatsis I., Efstradiatis A., and Goldman J.E. Insulin-like growth factor (IGF) signaling through type 1 IGF receptor plays an important role in remyelination. J. Neurosci. 23 (2003) 7710-7718
24. McMorris F.A. Cyclic AMP induction of the myelin enzyme 2′,3′-cyclic nucleotide 3′-phosphohydrolase in rat oligodendrocytes. J. Neurochem. 41 (1983) 121-132
25. McMorris F.A., Smith T.M., DeSalvo S., and Furlanetto R.W. Insulin-like growth factor I/somatomedin C: a potent inducer of oligodendrocyte development. Proc. Natl. Acad. Sci. U. S. A. 83 (1986) 822-826
26. Montminy M. Transcriptional regulation by cyclic AMP. Ann. Rev. Biochem. 66 (1997) 807-822
27. Mozell R.L., and McMorris F.A. Insulin-like growth factor I stimulates oligodendrocyte development and myelination in rat brain aggregate cultures. J. Neurosci. Res. 30 (1991) 382-390
28. + channels via PKA-independent mechanisms. Life Sci. 65 (1999) 109-114
29. Palacios N., Sánchez-Franco F., Fernández M., Sánchez I., and Cacicedo L. Intracellular events mediating the insulin-like growth factor I on oligodendrocyte development: modulation by cyclic AMP. J. Neurochem. 95 (2005) 1091-1107
30. Penn R.B., Parent J.L., Pronin A.N., Panettieri R.A., and Benovic J.L. Pharmacological inhibition of protein kinases in intact cells: antagonism of beta adrenergic receptor ligand binding by H89 reveals limitations of usefulness. J. Pharmacol. Exp. Ther. 288 (1999) 428-437
31. Pham N., Cheglakov I., Koch C.A., deHoog C.L., Moran M.F., and Rotin D. The guanine nucleotide exchange factor CNrasGEF activates Ras in response to cAMP and cGMP. Curr. Biol. 10 (2000) 555-558
32. Putz T., Culig Z., Eder I.E., Nessler-Menardi C., Bartsch G., Grunike H., Uberall F., and Klocker H. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res. 59 (1999) 227-233
33. Raible D.W., and McMorris F.A. Cyclic AMP regulates the rate of differentiation of oligodendrocytes without changing the lineage commitment of their progenitors. Dev. Biol. 133 (1989) 437-466
34. Raible D.W., and McMorris F.A. Induction of oligodendrocyte differentiation by activators of adenylate cyclase. J. Neurosci. Res. 27 (1990) 43-46
35. Raible D.W., and McMorris F.A. Oligodendrocyte differentiation and progenitor cell proliferation are independently regulated by cyclic AMP. J. Neurosci. Res. 34 (1993) 287-294
36. Rehmann H., Schwede F., Døskeland S.O., Wittinghofer A., and Boss J.L. Ligand-mediated activation of the cAMP-responsive guanine nucleotide exchange factor Epac. J. Biol. Chem. 278 (2003) 38548-38556
37. Roger P.P., Reuse S., Maenhaut C., and Dumont J.E. Multiple facets of the modulation of growth by cAMP. Vitam. Horm. 51 (1995) 59-191
38. de Rooij J., Zwartkruis F.J.T., Verheijen M.H.G., Cool R.H., Nijman S.M.B., Wittinghofer A., and Bos J.L. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 396 (1998) 474-477
39. de Rooij J., Rehmann H., van Triest M., Cool R.H., Wittinghofer A., and Bos J.L. Mechanism of regulation of the Epac family of cAMP-dependent RapGEFs. J. Biol. Chem. 275 (2000) 20829-20836
40. Satake N., Fujimoto S., and Shibata S. The potentiation of nitroglycerin-induced relaxation by PKG inhibition in aortic rings. Gen. Pharmacol. 27 (1996) 701-705
41. Sato-Bigbee C., and De Vries G.H. Treatment of oligodendrocytes with antisense deoxyoligonucleotide directed against CREB mRNA: effect on the cyclic-dependent induction of myelin basic protein expression. J. Neurosci. Res. 46 (1996) 98-107
42. Schmitt J.M., and Stork P.J.S. Cyclic AMP-mediated inhibition of cell growth requires the small G protein Rap1. Mol. Cell. Biol. 21 (2001) 3671-3683
43. Sevetson B.R., Kong X., and Lawrence J.C.J. Increasing cAMP attenuates activation of mitogen-activated protein kinase. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 10305-10309
44. Shiga H., Asou H., and Ito E. Advancement of differentiation of oligodendrocyte progenitor cells by a cascade including protein kinase A and cyclic AMP-response element binding protein. Neurosci. Res. 53 (2005) 436-441
45. Shirokawa J.M., Elisei R., Knauf J.A., Hara T., Wang J., Saavedra H.I., and Fagin J.A. Conditional apoptosis induced by oncogenic ras in thyroid cells. Mol. Endocrinol. 14 (2000) 1725-1738
46. Shosan M.C., Ljungdahl S., and Linder S. H-89 inhibits collagenase induction by phorbol ester through a mechanism that does not involve protein kinase A. Cell. Signal. 8 (1996) 191-195
47. Stork P.J.S., and Schmitt J.M. Crosstalk between cAMP and Map kinase signalling in the regulation of cell proliferation. Trends Cell Biol. 12 (2002) 258-266
48. Vanessa N., Wolthuis R.M.F., de Tand M.F., Janoueix-Lerosey I., Bos J.L., and de Gunzburg J. Identification and characterization of potential effector molecules of the Ras-related GTP-ase Rap2. J. Biol. Chem. 274 (1999) 8737-8745
49. Vossler M.R., Yao H., York R.D., Pan M.G., Rim C.S., and Stork P.J.S. cAMP activates MAP kinase and Elk-1 through a B-Raf and Rap1-dependent pathway. Cell 89 (1997) 73-82
50. Wang L., Liu F., and Adamo M.L. Cyclic AMP inhibits extracellular signal-regulated kinase and phosphatidylinositol 3-kinase/Akt pathways by inhibiting Rap 1. J. Biol. Chem. 276 (2001) 37242-37249
51. Warskulat U., Newsome W., Noe B., Stoll B., and Haussinger D. Anisoosmotic regulation of hepatic gene expression. Biol. Chem. Hoppe-Seyler 337 (1996) 57-65
52. Yao D.L., Liu X., Hudson L.D., and Webster H.F. Insulin-like growth factor-I treatment reduces demyelination and up-regulates gene expression of myelin-related proteins in experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 6190-6194
53. Yasunari K., Kohno M., Kano H., Yokokawa K., Minami M., and Yosikawa J. Dopamine D1-like receptor stimulation inhibits hypertrophy induced by platelet-derived growth factor in cultured rat renal vascular smooth muscle cells. Hypertension 29 (1997) 350-355
54. Ye P., Carson J., and D'Ercole A.J. In vivo actions of insulin-like growth factor-I (IGF-I) on brain myelination: studies of IGF-I and IGF binding protein-1 (IGFBP-1) transgenic mice. J. Neurosci. 15 (1995) 7344-7356
55. Yonehara T., Kanasaki H., Yamamoto H., Fukunaga K., Miyazaki K., and Miyamoto E. Involvement of mitogen-activated protein kinase in cyclic adenosine 3′-5′-monophosphate-induced hormone gene expression in rat pituitary GH3 cells. Endocrinology 142 (2001) 2811-2819
56. Won J.S., Lee J.K., and Suh H.W. Forskolin inhibits expression of inducible nitric oxide synthase mRNA via inhibiting the mitogen activated protein kinase in C6 cells. Brain Res. Mol. Brain Res. 89 (2001) 1-10
57. Zeger M., Popken G., Zhang J., Xuan S., Lu Q.R., Schwab M.H., Nave K.A., Rowitch D., D'Ercole A.J., and Ye P. Insulin-like growth factor type I receptor signalling in the cells of oligodendrocyte lineage is required for normal in vivo oligodendrocyte development and myelination. Glia 55 (2007) 400-411
58. Zhang H.H., Halbleib M., Ahmad F., Manganiello V.C., and Greenberg A.S. Tumor necrosis factor-alpha stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes 51 (2002) 2929-2935